EY-Parthenon supports MB Funds in their investment in Pharmatory Oy

On 2 February 2026 Pharmatory and MB Funds announced to have taken an important step to strengthen Pharmatory’s future growth trajectory. As part of the transaction, MB Funds has become a new strategic partner, supporting Pharmatory’s plans to expand and scale its operations in the API market.

Founded in 2001, Pharmatory is a long-established Finnish company specializing in small-molecule APIs and providing global pharmaceutical and biotechnology customers with process development, analytical services, and GMP manufacturing capabilities. With the new investment, the company is preparing to broaden its capabilities by advancing into the rapidly growing high-potency API (HPAPI) segment through planned facility development in Oulu.

EY-Parthenon supported the transaction by delivering a wide-ranging set of diligence services, including financial, tax, commercial, ESG and IT assessments. The team collaborated across these workstreams, drawing on life sciences and CDMO experience to assess the operating environment, examine market opportunities and understand the potential impact of the planned capacity expansion.

EY-Parthenon congratulates MB Funds and Pharmatory of the transaction and wishes the parties continued success in their growth journey.

Visit MB Funds and Pharmatory Oy to learn more.

Below you can find a selection of EY-Parthenon's recent deal alerts and you can also find a more extensive list on our Transactions and Corporate Finance by EY-Parthenon page.